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Abstract
Background: The pathogenesis of rabies is associated with the inability to deliver immune effectors across the blood-brain
barrier and to clear virulent rabies virus from CNS tissues. However, the mechanisms that facilitate immune effector entry
into CNS tissues are induced by infection with attenuated rabies virus.
Methodology/Principal Findings: Infection of normal mice with attenuated rabies virus but not immunization with killed
virus can promote the clearance of pathogenic rabies virus from the CNS. T cell activity in B cell–deficient mice can control
the replication of attenuated virus in the CNS, but viral mRNA persists. Low levels of passively administered rabies virus–
neutralizing antibody reach infected cells in the cerebellum of B cell–deficient mice but are not sufficient to mediate virus
clearance. Production of rabies virus-specific antibody by B cells invading CNS tissues is required for this process, and a
substantial proportion of the B cells that accumulate in the CNS of mice infected with attenuated rabies virus produce virus-
specific antibodies.
Conclusions/Significance: The mechanisms required for immune effectors to enter rabies virus-infected tissues are induced
by infection with attenuated rabies virus but not by infection with pathogenic rabies viruses or immunization with killed
virus. T cell activities can inhibit rabies virus replication, but the production of rabies virus–specific antibodies by infiltrating
B cells, as opposed to the leakage of circulating antibody across the BBB, is critical to elimination of the virus. These findings
suggest that a pathogenic rabies virus infection may be treatable after the virus has reached the CNS tissues, providing that
the appropriate immune effectors can be targeted to the infected tissues.
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Introduction
Rabies viruses spread from peripheral sites of entry to the
central nervous system (CNS) tissues via axonal transport thereby
bypassing the specialized features of the neurovasculature known
as the blood-brain barrier (BBB). Once the virus reaches CNS
tissues three alternative outcomes are likely: (1) the BBB remains
intact and the infection is lethal due to the absence of an antiviral
CNS immune response (2) immune effectors cross the BBB and
mediate a CNS antiviral immune response with extensive
immunopathology that contributes to the disease, or (3) immune
effectors cross the BBB and clear the virus from the CNS without
significant pathological consequences. It is well known that in
humans naturally infected with rabies virus the latter outcome is
exceedingly rare. In addition, CNS inflammation is generally
limited in individuals who succumb to rabies [1]. Consequently, it
is probable that the BBB remains intact through much of the
course of rabies infection in humans. In the absence of a
mechanism to compromise the barrier function of the neurovas-
culature, circulating rabies virus-specific immune effectors,
whether raised by the infection or by active or passive
immunization, would be unable to mediate an antiviral response
in CNS tissues. This may explain why conventional post-exposure
treatment of human rabies, consisting of active and passive
immunization, is unsuccessful if begun after the appearance of
signs of the disease [2–4]. At this stage of the infection the virus has
likely begun to replicate in the CNS. Thus, the primary function of
current post-exposure regimens may be limited to preventing the
virus from reaching CNS tissues.
Unlike humans where rabies viruses may take weeks to reach
the CNS from the site of exposure [5], the spread of most rabies
virus strains to the CNS in mice is rapid with virus generally being
detectable in CNS tissues within 48 hours of infection [6].
Nevertheless, normal mice survive infection with laboratory-
attenuated strains of rabies virus [7]. While certain of these viruses
may be deficient in the capacity to spread from the periphery to
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the CNS, most of the attenuated rabies virus variants that we have
tested spread to and replicate in the CNS but are cleared by
immune effectors that cross the BBB and infiltrate neural tissues
[7]. In contrast, BBB integrity is maintained and immune effectors
do not accumulate in the CNS tissues during infection of mice with
common pathogenic rabies virus strains, despite the development
of virus-specific immunity in peripheral lymphoid organs and
innate immunity in the infected CNS tissues [7,8]. These
observations have led us to speculate that the lethal outcome of
infection with wildlife and pathological strains of rabies virus is at
least in part due to the evasion of immune clearance as a
consequence of the maintenance of BBB integrity [8]. Perhaps the
best evidence that this may be the case is that disruption of the
BBB in mice infected with a highly lethal silver-haired bat-
associated rabies virus (SHBRV), by triggering autoimmune CNS
inflammation, promotes the clearance of the virus from the CNS
tissues and survival [9]. Due to the associated pathology, the
approach of using an autoimmune response to induce elevated
BBB permeability and permit rabies virus-specific immune
effectors to infiltrate CNS tissues is clearly inappropriate for use
in human rabies. On the other hand, the neuroimmune response
induced by infection with attenuated rabies virus, which also has
the appropriate specificity, is not associated with significant
pathology. In this study, we show that the functional changes in
the BBB required to deliver immune effectors to the CNS tissues
can be induced in mice infected with a lethal rabies virus strain by
immunization with a live-attenuated virus vaccine strain but not
by administration of killed virus vaccine. Furthermore, our data
suggests that clearance of rabies virus from CNS tissues is
dependent upon the production of virus-specific antibodies by
infiltrating B cells.
Methods
Animals, viruses, and antibody treatment
Eight to 12-week old wild-type control 129/SvEv and C57BL6
mice and JHD2/2 mice on a C57BL6 background were obtained
from the in-house breeding colony at Thomas Jefferson University.
RAG-22/2 mice on a 129/SvEv background were obtained from
Taconic (Germantown, NY). Mice were infected or immu-
nized intranasally (i.n.) with 105 focus forming units of CVS-F3,
CVS-N2c or UV-inactivated CVS-F3 in PBS as previously
described [10]. In some experiments, mice were infected and
immunized with a combination of the viruses. Where indicated,
CVS-F3-infected JHD2/2 mice were treated intraperitoneally
with 1 mg of the monoclonal, rabies virus glycoprotein-specific,
virus-neutralizing antibody 1112 in 500 ml of saline or with the
vehicle alone at the time points noted in the figure legends. All
procedures were carried out according to the protocols approved
by the Institutional Animal Care and Use Committee of Thomas
Jefferson University.
Assessment of blood-brain barrier integrity
BBB integrity was assessed by quantifying the leakage of a low
molecular weight fluorescent marker (Na-fluorescein, 376 kDa)
from the circulation into CNS tissues as previously described [10].
Briefly, 100 ml of 10% solution of Na-fluorescein was injected
intraperitoneally and after 10 minutes mice were anesthetized and
cardiac blood was collected followed by transcardial perfusion.
Serum samples as well as supernatants of homogenized and
centrifuged tissues were clarified by precipitating proteins with
15% TCA and the level of fluorescence measured with a
CytoFluor
TM
II fluorimeter. The amount of Na-fluorescein in
the CNS tissue is normalized to its level in serum by (mg of
Na-fluorescein in CNS tissue/mg of tissue)/(mg of Na-fluorescein
in serum/ml of serum) and is expressed as a fold increase in
fluorescence uptake by comparison with the results obtained from
naı¨ve controls.
Immunohistochemistry
For immunohistochemical analysis, brains from perfused mice
were snap frozen in Tissue-Tek O.C.T. Compound (Sakura
Finetex, Torrance, CA), sectioned using a Thermo Shandon
cryostat (Pittsburgh, PA), and fixed in either 80% acetone or 95%
ethanol. Immunoglobulin (Ig) was detected using either biotiny-
lated monoclonal rat anti-mouse kappa light chain (1 hour at 1:50)
(BD Pharmingen, San Jose, CA) followed by Alexa Fluor 568
streptavidin (1 hour at 1:1000) (Invitrogen, Eugene, OR) or the
VECTASTAIN ABC-AP KIT with polyclonal rabbit anti-mouse
biotinylated IgG (1:200) developed using the peroxidase antiper-
oxidase method and 393-diaminobenzidine as substrate (Vector
Laboratories, Burlingame, CA) according to the manufacturer’s
protocol. For the additional staining shown in one of the figure
panels (#3D), a 1 hour incubation with 1 mg/ml 1112 was
performed prior to detection of Ig. To assess virus infection
sections were stained for 1 hour with FITC-conjugated anti-rabies
virus nucleoprotein monoclonal antibody (1:50) (Centocor, Mal-
vern, PA). Photographs were taken with a Nikon digital camera on
an Olympus BX-60 microscope.
Real-time quantitative RT-PCR
Total RNA was isolated from CNS tissue samples and mRNA
expression levels of rabies virus nucleoprotein, CD4, CD8, IFN-c
and L13 in CNS tissues were measured by quantitative reverse-
transcriptase (RT)-PCR as previously described [10]. Real-time
quantitative RT-PCR was carried out on cDNA using specific
primer and probe sets and a Bio-Rad iCycler iQ Real Time
Detection System (Hercules, CA). The number of copies of specific
mRNAs in each sample was determined as previously described
[10] and normalized to the mRNA copy number of the
housekeeping gene L13 in that sample. Data are expressed as
Author Summary
Every year over 50,000 people die from rabies worldwide,
primarily due to the poor availability of rabies vaccine in
developing countries. However, even when vaccines are
available, human deaths from rabies occur if exposure to
the causative virus is not recognized and vaccination is not
sought in time. This is because rabies virus immunity
induced by the natural infection or current vaccines is
generally not effective at removing disease-causing rabies
virus from brain tissues. Our studies provide insight into
why this is the case and how vaccination can be changed
so that the immune response can clear the virus from brain
tissues. We show that the type of immune response
induced by a live-attenuated rabies virus vaccine may be
the key. In animal models, live-attenuated rabies virus
vaccines are effective at delivering the immune cells
capable of clearing the virus into CNS tissues and promote
recovery from a rabies virus infection that has spread to
the brain while conventional vaccines based on killed
rabies virus do not. The production of rabies-specific
antibody by B cells that invade the CNS tissues is
important for complete elimination of the virus. We
hypothesize that similar mechanisms may promote rabies
virus clearance from individuals who are diagnosed after
the virus has reached, but not extensively spread, through
the CNS.
Antibody Delivery to the CNS in Rabies Clearance
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the number of copies of mRNA for a particular gene in a sample
per copy of mRNA for the housekeeping gene L13 in that sample.
Isolation of mononuclear cells, flow cytometry, and
ELISPOT analysis
Mononuclear cells were prepared from peripheral blood
collected by retro-orbital bleeding in heparinized capillary tubes
by centrifugation at 300 g for 20 minutes. The white cell layer was
washed in PBS twice before analysis. Mononuclear cells were
isolated from CNS tissues as described elsewhere by isolation at
the interface of a 30/70 Percoll (Sigma) step gradient centrifuged
at 800 g for 25 minutes [11]. For flow cytometry, mononuclear
cells were suspended in staining buffer (PBS with 2% FBS and
0.1% NaN2) and incubated with anti-CD16/32 (1 ug/10
6 cells)
(2.4G2 BD Pharmingen, San Jose, CA) antibody to prevent non-
specific binding. Cells were washed in PBS and incubated with
anti-mouse CD19 (1:1000) (1D3, BD Pharmingen, San Jose, CA)
and MHC class-II (1:1000) (120.1, BD Pharmingen, San Jose, CA)
antibodies. Phenotypic characterization of antibody-labeled cells
was performed on a BD-FacsCaliber Flowcytometer. CD19-MHC
class II double-positive cells were defined as B cells. Numbers of
rabies virus-antigen specific antibody secreting B cells were
assessed using Millipore Multiscreen HAH ELISPOT plates coated
with 5 ug/mL of UV-inactivated whole rabies virus. Peripheral
blood or brain derived mononuclear cells were suspended in
RPMI media supplemented with 25 mM HEPES and 10% FBS
and 200,000 cells were incubated in each well for 18 hours. Plates
were washed and bound rabies virus-specific antibodies were
detected by addition of alkaline-phosphatase conjugated anti-
mouse IgG antibody (1:500) (Sigma, St. Louis, MO) followed by
BCIP/NBT substrate. Spots were counted using a dissecting
microscope.
Statistical analyses
Results are expressed as the mean6standard error mean
(S.E.M.). Statistical significance of the differences between groups
was tested using the Mann-Whitney test and the symbol * indicates
a p value,0.05.
Results
Lethal rabies virus infection can be prevented by
immunization with live-attenuated, but not killed rabies
virus
Mouse models are not considered to be particularly suited to
studies of post-exposure prophylaxis (PEP) with rabies due to the
rapid spread of the viruses to the CNS. However, our prior studies
suggest that the lethal outcome of rabies in mice is more a
consequence of the inability to deliver immune effectors into CNS
tissues than its spread [8]. In our view, the key feature is that BBB
integrity is maintained during infection with lethal rabies viruses,
while infection with attenuated rabies virus variants causes
enhanced BBB permeability and a virus-clearing CNS immune
response [7,10]. The reason for this difference could be that
infection with highly pathological rabies virus strains causes the
inhibition of immune mechanisms that mediate the changes in
BBB function necessary for rabies-specific immune effectors to
cross. Alternatively, these may not be triggered due to a subtle
difference in rabies virus immune mechanisms induced by
pathogenic and attenuated viruses. To distinguish between these
two possibilities, mice were infected with the attenuated CVS-F3
variant or immunized with killed CVS-F3 and then 3 or 5 days
later were super-infected with the pathogenic CVS-N2c rabies
virus. CVS-F3 was administered first because the virus spreads
to, and replicates in the CNS more slowly than CVS-N2c (data
not shown). The delays were limited to 3 and 5 days so that the
CVS-N2c infection would have the 48 hours required to spread to
the CNS before the appearance of serum rabies virus-specific
antibodies approximately 8 days following CVS-F3 infection [10].
To control for unanticipated effects caused by the administration
of either immunogen, groups of mice were also given both live
and inactivated CVS-F3. As shown in Table 1, administration
of an inactivated CVS-F3 vaccine preparation that is effective
when given several weeks before a CVS-N2c challenge does not
protect when given 3 or 5 days prior to challenge. On the other
hand, the majority of mice infected with CVS-F3 as recently as 3
days previously survive CVS-N2c infection regardless of whether
or not inactivated virus is also administered. These results suggest
that the processes required to clear pathogenic rabies virus from
CNS tissues are induced by infection but not immunization with
CVS-F3.
T cell activities promote long-term survival in CVS-F3-
infected mice but cannot clear the virus
JHD2/2 mice lack B cells but have functional T cells and,
unlike RAG-22/2 mice, which lack both T and B cells, are
capable of elevating fluid-phase BBB permeability in response to
the infection (Fig. 1A). These mice are therefore suitable for
analyzing the effects of antibody administration on CVS-F3
infection. As a preface to such studies we compared the course of
CVS-F3 infection in JHD2/2 and RAG-22/2 mice. As is the case
for wild-type mice infected with CVS-F3 [10], both JHD2/2 and
RAG-22/2 mice lose weight as the infection progresses (Fig. 1A).
However, while RAG-22/2 mice continue to lose weight and die
approximately 20 days following infection, up to 70% of JHD2/2
mice survive past this time-point, most showing a modest weight
gain (Fig. 1B). At the same time virus replication, which continues
to increase in RAG-22/2 mice, becomes reduced in the JHD2/2
mice (Fig. 1C). These JHD2/2 mice exhibit signs of rabies
infection including ataxia and partial paralysis but survive the
infection for extended periods of time ( .40 days). This raises the
possibility that T cell activities may be able to partly control the
virus infection independently of antibody. To gain insight into the
contributing T cell subsets, we compared the levels of CD4, CD8
and IFN-c mRNAs in CNS tissues from wild-type conventional
mice 24 days after CVS-F3 infection when there is little virus
replication remaining (see below) and JHD2/2 mice 40 days after
Table 1. Survival of mice immunized or infected with CVS-F3
prior to infection with CVS-N2c.
Initial Infection or
Immunization
Secondary Infection
(Delay in Days)
Survival
(Percent)
None CVS-N2c 0/5 (0)
CVS-F3, live none 5/5 (100)
CVS-F3, live CVS-N2 c (3) 4/5 (80)
CVS-F3, live CVS-N2c (5) 5/5 (100)
CVS-F3, inactivated CVS-N2c (3) 0/5 (0)
CVS-F3, inactivated CVS-N2c (5) 0/5 (0)
CVS-F3, inactivated CVS-N2c (21) 10/10 (100)
CVS-F3, live and inactivated CVS-N2c (3) 3/5 (60)
CVS-F3, live and inactivated CVS-N2c (5) 5/5 (100)
doi:10.1371/journal.pntd.0000535.t001
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infection. As can be seen in Fig. 2, the levels of CD4 and CD8
mRNA are somewhat lower in the JHD2/2 mice but IFN-c
mRNA levels have remained relatively high and may therefore be
contributing to the control of virus replication.
Leakage of antibody across the BBB may not be sufficient
to clear CVS-F3 from CNS tissues
The inability of JHD2/2 mice to clear CVS-F3 from the CNS
reaffirms the importance of rabies virus-specific antibodies in this
process. However, little is known with respect to how these
antibodies may be delivered to infected CNS tissues. Our studies
of mice clearing CVS-F3 suggest that the leakage of naturally
developing antibodies from the circulation into the CNS tissues
may be minimal since elevated BBB permeability occurs before
serum antibody titers peak [10]. In addition, over the short term,
extensive fluid phase exchange across the BBB is seen but little
accumulation of markers of the molecular mass of antibody is
detectable [12]. Nevertheless, it may be expected that some
antibody would cross the BBB in conjunction with infiltrating
immune cells and, over time, sufficient levels may accumulate to
impact virus replication. To examine this possibility, JHD2/2
mice were treated with 1 mg of the mouse IgG1 monoclonal rabies
virus-neutralizing, glycoprotein-specific antibody 1112, which is
highly effective in post-exposure treatment models [13], on each of
days 7 and 9 post-infection when BBB permeability is at a peak.
Several hours later, CNS tissues were obtained and stained with
antibodies specific for rabies nucleoprotein and for mouse IgG to
determine if there was any antibody associated with infected cells.
While extensive infection of Purkinje cells can be readily detected
with nucleoprotein-specific antibodies in sections from the
cerebellum of JHD2/2 mice (Fig. 3A), as expected, there is no
evidence of IgG in sections from animals that had not received
antibody (Fig. 3B). IgG-specific staining of Purkinje cells in sections
from mice receiving 1112 antibody could be detected (Fig. 3C) but
the treatment of these sections with additional 1112 antibody in
vitro prior to IgG detection resulted in more extensive staining
(Fig. 3D). When cells stained for both nucleoprotein (Fig. 3E,G
green) and antibody (Fig. 3F,G red) were examined more closely,
distinct inclusions of nucleoprotein and antibody/glycoprotein can
be seen. These findings suggest that low levels of 1112 antibody
can leak from the circulation to interact with rabies virus-infected
cells in the CNS tissues provided that their application coincides
with elevated BBB permeability.
To determine whether 1112 antibody administration to CVS-
F3-infected JHD2/2 mice leads to the clearance of the virus from
CNS tissues, we administered saline or 1 mg of the antibody 5
times at two day intervals between days 7 and 15 post-infection.
This antibody dose regimen achieved a half-maximal serum
rabies-specific antibody titer of approximately 1/240, which is
roughly equivalent to the serum titer found in normal mice 8 days
post-infection with CVS-F3, during the period of time when BBB
permeability is maximal. Viral nucleoprotein mRNA levels in the
CNS tissues of surviving animals, both saline and antibody treated,
were substantial several weeks later (Fig. 4) at a time when they are
virtually undetectable in wild-type mice [10]. Moreover, no impact
on the health or survival of the mice was noted.
Figure 1. The T cell response to CVS-F3 infection in the absence of B cells mediates enhanced BBB permeability and long-term
survival. The extent of BBB permeability in the cerebellum of wild-type, JHD2/2 and RAG-22/2 mice, infected i.n. with CVS-F3 10 days previously, is
shown in panel A. Weight loss over the course of infection in JHD2/2 and RAG-22/2 mice is shown in panel B, while the number of copies of rabies
virus nucleoprotein mRNA at different times of infection in these animals is presented in panel C. BBB permeability changes are shown as the
mean6S.E.M. fold increase in Na-Fluorescein uptake in the tissues with the levels from uninfected mice taken as 1. Weight is expressed as the
mean6S.E.M. percent body weight with the weight on day 0 being taken as 100% and copies of nucleoprotein mRNA in the tissues are expressed per
copy of L13 mRNA in the same sample.
doi:10.1371/journal.pntd.0000535.g001
Figure 2. Prolonged IFN-c mRNA expression in the CNS tissues
of CVS-F3-infected JHD2/2 mice. Wild-type and JHD2/2 mice were
infected i.n., with CVS-F3 and euthanized at 24 or 40 days following
infection to assess CD4, CD8 and IFN-c mRNA levels using quantitative
RT-PCR. Data is expressed as the mean6S.E.M. fold increase with the
levels in tissues from uninfected mice taken as 1.
doi:10.1371/journal.pntd.0000535.g002
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Clearance of rabies virus from CNS tissues is dependent
upon antibody production by infiltrating B cells
CVS-F3 clearance from the CNS tissues of wild-type mice
occurs prior to the development of high titers of circulating virus-
neutralizing antibodies (VNA) and after BBB permeability has
peaked [10]. However, B cells that have infiltrated the CNS tissues
express high levels of k-light chain mRNA during this time period
indicating that there is likely to be substantial antibody production
in the CNS tissues [10]. To assess this possibility more directly, we
used antibodies specific for mouse IgG to stain CNS tissues from
wild-type mice infected 12 days previously with CVS-F3.
Extensive foci of antibody are seen throughout the cerebellum
(Fig. 5). At higher magnification the antibodies appear to be
diffusing in stellate patterns from the foci (Fig. 5). To determine if
B cells may be the source of these antibodies and whether or not
they are likely to be rabies virus-specific, we assessed rabies virus-
specific antibody production by B cells from the peripheral blood
and CNS tissues of CVS-F3-infected mice. While the proportion
of CD19+ B cells in mononuclear cells recovered from the CNS
tissues of CVS-F3-infected mice is lower than in peripheral blood
from the same animals, the fraction of the cells that produce rabies
virus-specific antibodies is considerably higher (Fig. 6). This
suggests that B cells producing rabies virus-specific antibodies
either selectively invade or expand in the CNS tissues in response
to CVS-F3 infection.
Discussion
Prompt administration of PEP is the recommended course for
an individual who has come in contact with a rabid animal. Since
this prevents the development of clinical rabies it is impossible to
be certain how many of the tens of thousands of people who
receive PEP on an annual basis have actually been infected with
the virus. It is also impossible to know how far the rabies virus may
have spread before being cleared by the immune effectors
provided or induced by PEP and the infection. The commonly
held view that pathogenic wildlife rabies virus that has spread to
the CNS cannot be cleared by immune mechanisms is supported
by the absence of significant immune cell infiltration into the CNS
tissues of individuals who die from rabies [1] and the failure of
Figure 3. Rabies virus specific antibodies administered to CVS-F3-infected JHD2/2mice have limited access to infected CNS tissues.
At 7 and 9 days post-infection, CVS-F3-infected JHD 2/2 mice were treated with 1 mg of the rabies glycoprotein-specific, virus-neutralizing mouse
monoclonal antibody 1112 (A, C, D, E, F, G) or saline vehicle alone (B). Several hours after the second treatment mice were transcardially perfused, CNS
tissues removed and sections from the cerebellum were stained for rabies virus infection with FITC-anti-nucleoprotein monoclonal antibody (panels A
and E; green), polyclonal rabbit anti-mouse biotinylated IgG (panels B and C; brown), additional 1112 antibody followed by the polyclonal rabbit anti-
mouse biotinylated IgG (panel D; brown), or a combination of FITC-anti-nucleoprotein monoclonal antibody and rhodamine-conjugated anti-mouse
Ig. Arrows in panels A-D identify Purkinje cells, a cell population that is extensively infected. Panels E-G show close-ups of a single cell stained with
FITC-anti-nucleoprotein monoclonal antibody and rhodamine-conjugated anti-mouse Ig photographed using filters for FITC (panel E), rhodamine
(panel F) and a combination red/green filter that shows both stains simultaneously (panel G).
doi:10.1371/journal.pntd.0000535.g003
Figure 4. The administration of rabies virus neutralizing
antibodies fails to clear CVS-F3 from the CNS of JHD2/2 mice.
JHD 2/2 mice were infected i.n. with CVS-F3 and treated at 7, 9, 11, 13,
and 15 days post-infection with saline vehicle alone or the rabies-
specific antibody 1112. Three weeks after the final treatment mice were
transcardially perfused, cerebellar tissues were removed, and virus
replication was estimated by quantifying nucleoprotein mRNA levels.
Virus replication was similarly estimated in cerebellar tissues from wild-
type mice infected with CVS-F3 24 days previously. Virus replication is
expressed as the mean6S.E.M. copies of rabies virus nucleoprotein
mRNA per copy of the housekeeping gene L13 mRNA in the tissue
sample.
doi:10.1371/journal.pntd.0000535.g004
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PEP in individuals that have developed signs of rabies [2,4]. Our
studies in animal models of rabies suggest that this is a
consequence of the inability of virus-specific immune effectors to
cross the BBB and enter CNS tissues infected with pathogenic
rabies viruses [7,8]. The rabies virus-specific immune effectors that
are raised in lethally infected mice are able to clear rabies virus
from the CNS if provided access across the BBB. For instance,
when the BBB is compromised by the induction of autoimmune
CNS inflammation, rabies-specific immune effectors infiltrate
CNS tissues and can clear the highly pathogenic SHRBV [9]. In
addition, the adoptive transfer of immune effectors recovered from
mice lethally infected with SHBRV results in clearance of the
attenuated CVS-F3 virus from the CNS tissues of mice lacking T
and B lymphocytes [8]. In contrast, the transfer of cells from mice
clearing CVS-F3 has no impact on the outcome of SHBRV
infection [8]. Regardless of the infecting virus strain, elements of
the innate immune response that are important for the early
control of virus replication and for attracting immune cells into
infected tissues are induced [7,8,10]. These findings led us to
speculate that functional changes at the BBB required to provide
immune effectors access to the CNS tissues are induced during
infection with attenuated rabies virus strains but not during
pathological rabies virus infection [7–9]. A key issue examined in
this study is whether or not this is due to an inhibitory process
triggered by infection with pathogenic rabies virus. If so, it may be
Figure 5. Pattern of antibody appearance in the CNS tissues of CVS-F3-infected mice. Sections from the cerebella of wild-type mice either
uninfected (A and C) or infected with CVS-F3 12 days previously (B and D) were stained for IgG (brown). Photomicrographs taken at low magnification
are shown in panels A and B and at higher magnification in C and D.
doi:10.1371/journal.pntd.0000535.g005
Figure 6. Rabies virus-specific antibody secreting B cells
accumulate in the CVS-F3-infected CNS. Mononuclear cells
isolated from peripheral blood lymphocytes (PBL) and brain (CNS)
were assessed for surface phenotype using flow cytometry and for the
numbers of rabies virus-specific antibody secreting cells by ELISPOT.
The percentage of B cells, identified as positive for both CD19 and MHC
class II, among total mononuclear cells is presented on the left side of
the figure while the proportion of the total mononuclear cells
producing rabies virus-specific antibodies is presented on the right
side of the figure.
doi:10.1371/journal.pntd.0000535.g006
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expected that BBB integrity would be maintained during infection
with both pathogenic and attenuated rabies viruses and the
outcome would be lethal, but it is not. Infection with an attenuated
rabies virus induces BBB integrity changes and immune effector
entry into CNS tissues regardless of whether or not there is also an
ongoing infection with pathogenic rabies virus. However,
protection is not provided by immunization with killed virus. We
therefore conclude that the generation of a rabies virus-specific
immune response in the periphery is not sufficient to clear
pathogenic rabies viruses from the CNS tissues. A mechanism
selectively induced by infection with attenuated rabies virus, likely
manifested at the BBB, is necessary to provide immune effectors
access to CNS tissues.
To gain further insight into the mechanism of rabies virus
clearance from the CNS tissues, we have used gene-deleted mice
to study the role(s) of different antiviral immune effectors in the
CNS tissues of mice clearing the attenuated rabies virus CVS-F3.
Mice lacking T and B cells cannot clear this virus and die from the
infection [8,14]. CD8 T cells contribute to, but are not required
for the clearance of CVS-F3 as clearance is merely delayed in mice
without this cell population [14,15]. On the other hand, JHD2/2
mice, which lack B cells but have functional CD4 and CD8 T cells,
often survive CVS-F3 infection over extended periods despite
being unable to clear virus from CNS tissues and exhibiting
neurological symptoms. This leads us to conclude that elements of
the T cell response, likely including IFN-c production by CD4 and
CD8 T cells, can control certain features of the infection that make
significant contributions to its lethality but that antibody is
required for virus clearance. To examine the contribution of
circulating antibody to virus clearance from CNS tissues, we
administered high levels of the rabies virus neutralizing mouse
monoclonal 1112 antibody to CVS-F3-infected JHD2/2 mice
during the stage of infection when BBB permeability is maximal.
While leakage of a 150 kDa molecular weight marker from the
circulation into the CNS tissues of CVS-F3-infected mice is
minimal over a 4-hour period [12], antibodies present in the
circulation over a more extensive period of time can evidently leak
into the CNS tissues of the infected mice. 1112 antibody was found
associated with the Purkinje cells in the cerebellum that express
high levels of rabies virus antigen. The antibody was primarily
localized in inclusion bodies which is consistent with previous in
vitro studies showing that 1112 antibody is rapidly internalized by
rabies virus-infected neuroblastoma cells where it accumulates in
intracellular vesicles [13]. Of note in our studies is that the
intracellular inclusions of glycoprotein-specific 1112 are generally
distinct from inclusions of the virus nucleoprotein. The amounts of
antibody reaching rabies virus-infected cells in vivo appears to be
relatively low as considerably greater amounts of the antibody can
bind to the cells when applied to tissue sections in vitro. While it is
possible that even low levels of virus-neutralizing antibody may
impact the replication and spread of the virus while BBB
permeability is enhanced, treatment of CVS-F3-infected JHD2/2
mice with 1112 antibody failed to clear the virus.
It should be noted with respect to the origin of the antibodies
that participate in rabies virus clearance that serum rabies virus-
specific antibody titers peak some time after BBB integrity has
been restored [10]. The presence of cells expressing the B cell
phenotypic marker CD19 and mRNAs specific for k- light chain
in the CNS tissues of mice clearing CVS-F3 [8,10] led us to
examine the possibility that rabies virus-specific antibodies are
produced by infiltrating B cells. The current findings indicate that
this is the case. Focal concentrations of antibodies can be readily
detected in the CNS tissues of mice clearing CVS-F3 and a high
proportion of B cells recovered from the tissues produce rabies
virus-specific antibodies in vitro. This leads us to conclude that the
high levels of antibodies required for rabies virus clearance from
the CNS tissues are produced at the site of infection rather than
diffusing in from the circulation. In this case, passively adminis-
tered antibody during PEP would primarily impact virus in the
periphery and an active immune response leading to elevated BBB
permeability and immune effector delivery to the CNS tissues
would likely be required to clear virus from the CNS.
As certain of the aspects of BBB function required for immune
cell infiltration are unchanged by CNS infection with pathogenic
rabies viruses [8], once the virus has reached the CNS a PEP
protocol capable of altering the BBB, so that virus-specific immune
effectors can reach the infected tissues, is required. Inactivated
CVS-F3 can induce rabies virus-specific T and B cells, but fails to
promote recovery from CVS-N2c infection over a time frame
during which the administration of live CVS-F3 is therapeutic. We
consider that this is a consequence of the inability of the
inactivated virus to induce the functional changes in the BBB
that are required for antiviral immune effectors to enter CNS
tissues. In our view, administration of a live-attenuated rabies virus
vaccine is the most reasonable, currently available, approach to
providing the appropriate immune effectors access to the CNS
tissues. The results of our experiments with a new, highly
attenuated recombinant rabies virus vaccine which expresses
three copies of a mutated glycoprotein gene, strongly support this
hypothesis [16]. In these studies, the triple G vaccine was shown to
promote immune effector delivery into CNS tissues and normal
mice were found to survive the intracranial injection of a mixture
of the vaccine virus and a highly pathogenic dog strain which was
nearly 100% lethal when administered alone [16]. The triple G
vaccine also proved effective in the post-exposure treatment of
mice infected with a highly pathogenic dog rabies virus several
days previously [16]. However, when UV-inactivated and given
peripherally to mimic conventional post-exposure vaccination,
there was little protective effect [16]. In addition to boosting the
antiviral response, attenuated rabies virus vaccines spread to the
CNS where they trigger the mechanisms required for T cells and B
cells to enter the tissues and clear, not only the attenuated, but also
pathogenic rabies viruses. It is clear from the commonly lethal
outcome of rabies that these mechanisms are not induced in a
timely fashion in the context of the spread of a wildlife rabies virus
to the human CNS.
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